Apo(a) phenotyping and long-term prognosis for coronary artery disease. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Clinical Biochemistry Year : 2010

Apo(a) phenotyping and long-term prognosis for coronary artery disease.

Abstract

Objectives Identify whether the plasma concentration of Lp(a), apo(a) size or a greater affinity for fibrin predict the likelihood of cardiac death, non-fatal myocardial infarction, unstable angina, the need for additional revascularization, and stroke (MACCE). Design and methods We analyzed the clinical prognosis of 68 patients with coronary artery disease included in a case-controlled study which evaluated Lp(a) concentration, apo(a) size, and Lp(a) fibrin-binding. Cohort was conducted over a median of 8 years. We used Kaplan–Meier survival tables to evaluate cardiovascular and cerebrovascular events in the follow-up period. Results Apo(a) isoforms of small size are predictors of MACCE. We find an association between Lp(a) concentration and apo(a) fibrin-binding with major adverse cardiovascular and cerebrovascular events, although without statistically significant results. Conclusions Small-sized apo(a) isoforms are an independent risk factor for MACCE in patients with coronary artery disease in follow-up. Lp(a) plasma concentration and apo(a) fibrin-binding were associated, although not significant.
Fichier principal
Vignette du fichier
APO_a_PHENOTYPING_AND_LONG-TERM_PROGNOSIS_FOR_CORONARY_ARTERY_DISEASE.pdf (280.84 Ko) Télécharger le fichier
Origin Files produced by the author(s)
Loading...

Dates and versions

inserm-00524992 , version 1 (10-10-2010)

Identifiers

Cite

M. A. Baños-González, M. A. Peña-Duque, Eduardo Anglés-Cano, M. A. Martinez-Rios, A. Bahena, et al.. Apo(a) phenotyping and long-term prognosis for coronary artery disease.: Apo(a) phenotype and coronary artery disease.. Clinical Biochemistry, 2010, 43 (7-8), pp.640-4. ⟨10.1016/j.clinbiochem.2010.01.013⟩. ⟨inserm-00524992⟩
168 View
266 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More